By Fineline Cube Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196; HKG: 2196) announced that China’s National Medical Products Administration (NMPA) has approved a clinical trial evaluating HLX43, a novel PD-L1-targeting antibody-drug conjugate (ADC), in combination with bevacizumab for the treatment of advanced/metastatic solid tumors.
Clinical Development Milestone
| Item | Detail |
|---|---|
| Sponsor | Henlius Therapeutics (Fosun Pharma subsidiary) |
| Compound | HLX43 (PD-L1 ADC) |
| Trial Design | Combination with bevacizumab ± chemotherapy |
| Indication | Advanced/metastatic solid tumors |
| Regulatory Body | NMPA (China) |
| Approval Date | 03 Aug 2026 |
| Development Stage | Phase I/II clinical trial |
Drug Profile & Innovation
- Molecule: HLX43 – a PD-L1-targeting antibody-drug conjugate (ADC)
- Payload Technology: Novel DNA topoisomerase I inhibitor small-molecule toxin–peptide linker (licensed technology)
- Antibody Component: Independently developed PD-L1-targeting monoclonal antibody
- Dual Mechanism: Combines immune checkpoint inhibition with targeted cytotoxic payload delivery
- Therapeutic Rationale: Enhanced anti-tumor efficacy through simultaneous immune activation and direct tumor cell killing
Strategic Context & Market Implications
- China’s ADC Landscape: Represents Henlius’ strategic entry into the rapidly growing antibody-drug conjugate market, projected to reach $8 billion in China by 2030
- Competitive Positioning: Differentiates from existing PD-L1 monotherapies through enhanced potency and potential for overcoming resistance mechanisms
- Combination Strategy: Leverages bevacizumab’s established anti-angiogenic effects to potentially improve drug delivery and tumor microenvironment modulation
- Pipeline Progression: Builds on HLX43’s previous clinical approvals as monotherapy and in other combination regimens, demonstrating Henlius’ systematic development approach
- Fosun Pharma Portfolio: Strengthens Fosun’s oncology pipeline alongside its biosimilars business, supporting the company’s transition toward innovative therapeutics
Development Outlook
- Trial Objectives: Initial focus on dose escalation and safety assessment, followed by efficacy evaluation across multiple solid tumor types
- Regulatory Pathway: Potential for accelerated approval based on unmet medical need in refractory solid tumors
- Commercial Potential: Addresses significant market opportunity in China’s growing oncology segment, where domestic innovation is increasingly favored by healthcare policies
- Global Ambitions: Successful development could support future international regulatory submissions and partnership opportunities
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory approvals, and commercial expectations for HLX43. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.-Fineline Info & Tech